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a b s t r a c t
IgA nephropathy (IgAN) patients have elevated serum levels of immune complexes consisting of IgA1 with
galactose-deﬁcient hinge-region O-glycans (Gd-IgA1) and anti-glycan IgG. These immune complexes deposit
in the kidney and activate mesangial cells. To conﬁrm that the activity of these immune complexes depends
on the interaction of Gd-IgA1 with anti-glycan IgG, we generated in vitro analogous immune complexes
using Gd-IgA1 myeloma protein and anti-glycan IgG from cord blood of healthy women. The Gd-IgA1 and
anti-glycan IgG from cord-blood serum formed IgA1–IgG immune complexes that resembled those in sera
of patients with IgAN. Furthermore, the ability to activate cellular proliferation was dependent on a heat-
sensitive serum factor. In summary, we developed a new protocol for in-vitro formation of IgA1–IgG immune
complexes, thus providing a new tool for studies of the pathogenesis of IgAN.
c© 2012 Elsevier B.V.
1. Introduction
IgA nephropathy (IgAN) is characterized by IgA-containing im-
mune complexes in the glomerular mesangium [1,2], with IgA exclu-
sively of the IgA1 subclass [3]. IgA1 can be co-depositedwith comple-
ment C3 and IgG or IgM or both [1,2]. Mesangial cellular proliferation
and expansion of extracellularmatrix are typical histological features.
These glomerular changes lead to end-stage renal failure in 20–40%
patients within 20 years of diagnosis [4–7]. The disease onset and/
or recurrent episodes of macroscopic hematuria often coincide with
mucosal infections, including those of upper respiratory tract and
digestive system [4,8–11].
There is considerable evidence indicating that the mesangial de-
posits originate from circulating IgA1-containing immune complexes
[12–24]. Analysis of the glycosylation of IgA1 in patients with IgAN
has provided new insights into themechanisms underlying immune-
complex formation and activation of mesangial cells [21,24–27].
Speciﬁcally, circulating immune complexes in IgAN contain IgA1with
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galactose (Gal)-deﬁcient hinge-regionO-linked glycans [21,24,25,28–
33] andGal-deﬁcient IgA1 is the predominant glycosylation variant of
IgA1 in themesangium [34,35]. A relationship betweenGal deﬁciency
and nephritis also has been observed in other diseases: Gal-deﬁcient
IgA1 [36,37] and IgA–IgG circulating complexes [38] are found in sera
of patients with Henoch–Schoenlein purpura who develop nephritis
but not in sera of those patients who do not. Also, patients with IgA1
multiple myeloma have high levels of circulating IgA1, but only in-
dividuals with the aberrantly-glycosylated variant develop immune-
complex glomerulonephritis [39,40].
In IgAN, the aberrant glycansorhinge-regionglycopeptides of IgA1
are recognized by naturally occurring IgG and/or IgA1 anti-glycan
antibodies and immune complexes are formed [21,24,41–44]. These
IgA1-containing immune complexes are of a relatively large molec-
ular mass [26,30,33] and, thus, are not efﬁciently cleared from the
circulation by the liver and tend to deposit in the renal mesangium
[45–50].
As only humans and hominoid primates have IgA1 [51], studies
of IgAN have been hampered by the lack of appropriate animal mod-
els. Alternatively, cultured primary human mesangial cells present
a convenient model to evaluate biologic activities of IgA1 complexes
[25,26,30,52–64]. Using thismodel,we andothers havedemonstrated
that immune complexes from sera of patients with IgAN containing
galactose-deﬁcient IgA1 activate mesangial cells and induce cellular
proliferation [26,30,62,64,65].
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Extensive studies of the detailed glycan structures of IgA1, ﬁne
speciﬁcities of anti-glycan antibodies, and biological activities are
hampered by the low quantity of immune complexes isolated from
sera of patients with IgAN. Therefore, to address this shortcoming, we
developed a new protocol for in-vitro production of biologically ac-
tive IgA1-containing immune complexes. We used cord-blood serum
with high levels of anti-glycan IgG to bind to IgA1 myeloma proteins
with Gal-deﬁcient hinge-region O-glycans that mimic the aberrant
IgA1 eluted from glomeruli of patients with IgAN [24,34,35,66–68] to
form immune complexes. The advantage of cord-blood serum is that
it contains almost exclusively IgG, with only trace amounts of IgM
or IgA. Our results showed that formation of the biologically active
immune complexes required Gal-deﬁcient IgA1, anti-IgA1 IgG anti-
body, and a heat-sensitive serum factor. Future studies to identify this
factor(s) and describe detailed mechanisms of immune-complex for-
mation will help in designing a better therapeutic target in patients
with IgAN.
2. Materials and methods
2.1. Serum samples
Cord-blood serum samples were collected from ﬁve pregnant
women (one Caucasian and four African Americans) at the time of
delivery. The donors did not have any evidence of renal disease as
determined by normal values for serum creatinine concentration and
urinary protein/creatinine ratio, and the absence of hematuria by
urinalysis testing. Serum samples were obtained from three biopsy-
proven IgAN patients and a healthy control. The UAB Institutional
Review Board approved the study and informed written consent was
obtained from each participant before collecting the blood samples.
2.2. IgA myeloma proteins
Two polymeric IgA1 (Mce and Gou) and one polymeric IgA2 (Fel)
myeloma proteins were prepared from plasma of patients with IgA
multiple myeloma [24,69]. Both IgA1 myeloma proteins had Gal-
deﬁcient hinge-region O-glycans [24,29].
2.3. Fractionation of immune complexes
Serum samples from patients with IgAN or healthy controls (0.5
ml) were ﬁltered using 0.45μm ﬁlter (Pall Corporation, Ann Arbor,
MI, USA) and fractionated on a calibrated Superose 6 column (600
× 12mm; Amersham Biosciences Corporation, Piscataway, NJ, USA)
in phosphate-buffered saline (PBS). For cord-blood serum supple-
mented with IgA, a mixture of 160μl cord-blood serum, 80μg IgA
myeloma protein and PBS to a ﬁnal volume of 500μl was incubated
at 4 ◦C overnight, ﬁltered and fractionated on a calibrated Superose 6
column. Fractions containing proteins of molecular mass apparently
over 700kDawere collected and every two fractionswere pooled and
added to the culturedmesangial cells [70]. IgA and IgG–IgA complexes
were determined in the fractions by ELISA [25,71].
2.4. Cell cultures
Humanmesangial cellswere purchased fromCambrex Bio Science
Walkersville, Inc. (Walkersville, MD, USA) and cultured, as described
[25]. Cells from passages 3 or 4 were maintained in RPMI 1640 sup-
plemented with 20% fetal calf serum (FCS), l-glutamine (2mmol/l),
penicillin G (100U/ml) and streptomycin (0.1mg/ml) in humidiﬁed
5% CO2 atmosphere at 37
◦C. Twenty-four-well tissue-culture plates
were seeded with the mesangial cells for proliferation experiments.
At 85%–95% conﬂuence, the mesangial cells were serum-starved in a
medium containing 0.5% FCS for 24h before experiments [70].
2.5. Proliferation assays
Proliferation of the cultured humanmesangial cells wasmeasured
by 3H-thymidine uptake, as described [26,70]. Serum from healthy
control or patient with IgAN or cord-blood serumwas supplemented
with IgA proteins and incubated at 4 ◦C overnight (unless otherwise
stated). Then, the samples were ﬁlter-sterilized, mixed with culture
medium containing 0.5% FCS, added in duplicates to mesangial cells,
and the cells were incubated for 20h at 37 ◦C in 5% CO2 atmosphere
and then analyzed [26,70]. The culture medium supplemented with
10ng/ml platelet-derived growth factor (PDGF; R&D Systems, Min-
neapolis, MN, USA) was used as a positive control. Medium alone
served as a negative control. Average valueswere calculated from du-
plicates for each serum fraction and expressed relative to the negative
control (cpm of sample/ cpm of the control) as relative proliferation.
Alternatively, the data were expressed as Δcpm, calculated as cpm
value of each sample from which the value measured for the control
sample was subtracted.
2.6. ELISA
For IgA detection, polystyrene microtiter plates (Nalge Nunc In-
ternational, Rochester, NY, USA) were coated overnight with 1μg/ml
goat anti-human IgA (Jackson ImmunoResearch Labs,West Grove, PA,
USA) [25,71]. After washing and blocking with 1% bovine serum albu-
min (BSA; Sigma Chemical Company, St Louis, MO, USA) in PBS con-
taining 0.05% Tween-20, serial 2-fold dilutions of duplicate samples
and standard serum (The Binding Site, Birmingham, United Kingdom)
in blocking solution were incubated overnight at room temperature.
The bound IgA was detected by incubation with biotin-labeled goat
anti-human IgA (BioSource International, Camarillo, TX, USA) for 3h
at 37 ◦C, followed by 1-h incubation with horseradish peroxidase-
conjugated ExtrAvidin (Sigma). o-Phenylenediamine–H2O2 (Sigma)
was used as substrate for peroxidase, and color development was
stopped with 1M sulphuric acid. The absorbance at 490nm was
measured using an automated ELISA reader (Bio-Tek Instruments
Winooski, VT, USA). The concentrations were calculated based on
calibration curves generated from standard serum. The results were
expressed in μg/ml.
For measurement of IgG–IgA complexes, 50-fold-diluted fractions
were applied on ELISA plates coated with goat anti-human IgG (Jack-
son ImmunoResearch Labs) and detected with biotin-labeled goat
anti-human IgA (BioSource) and developed, as described above. In-
ternal controls were included.
2.7. Depletion of IgA and IgG, and isolation of IgG
To remove IgA1 from serum of a patient with IgAN, serum was
adsorbed on immobilized jacalin (1-ml bed volume; EY Laboratories,
San Mateo, CA, USA), a lectin speciﬁc for O-glycans on IgA1. IgG was
depleted from serum or cord-blood serum using GammaBind Plus
Sepharose (Amersham Biosciences Corporation), using 1ml of the
samplemixedwith the sameamountof bindingbuffer (0.01Msodium
phosphate, 0.15M NaCl, 0.01M EDTA, pH 7.0). The ﬂow-through was
concentrated onAmiconUltra-4 PL-50 Centrifugal Filter Devices (Mil-
lipore, Billerica,MA,USA) to avolumeof1ml andusedas IgG-depleted
serum. To isolate IgG, the GammaBind Plus Sepharose column was
washed with 5ml binding buffer and the bound IgG was eluted with
acidic buffer (0.5M acetic acid adjusted to pH 3.0 with ammonium
hydroxide) and the pH was adjusted to neutral with Tris–HCl buffer.
Then, the IgG samples were desalted on a PD-10 column (GE Health-
Care, Chalfont St. Giles, United Kingdom) equilibrated with PBS, and
concentrated onAmiconUltra-4 PL-50 Centrifugal Filter Devices (Mil-
lipore) to 1ml volume. Purity of these samples was assessed after
separation by SDS-PAGE under reducing conditions by silver staining,
and by Western blotting with IgA- or IgG-speciﬁc antibodies.
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2.8. Western blot
Proteins separated by SDS-PAGE were blotted on Immobilon P
(Millipore) and detected with biotinylated goat IgG against hu-
man IgA or IgG (Vector Laboratories, Burlingame, CA, USA) followed
by horseradish peroxidase-conjugated NeutrAvidin (Pierce Chemical
Company, Rockford, IL, USA). The detection of IgA or IgG was accom-
plished by chemiluminescence using Supersignal substrate (Pierce)
and visualization on Biomaxﬁlm (Amersham, Biosciences Corp.) [70].
2.9. Statistical analyses
Data were expressed as mean ± SD or median values. Statistical
analyseswere performed using 2-tailed Student’s t testwith StatView
5.0 software (SAS). P value <0.05 was considered signiﬁcant.
3. Results
3.1. In vitro-formed immune complexes containing Gal-deﬁcient IgA1
stimulate proliferation of cultured primary human mesangial cells
Various concentrations of Gal-deﬁcient IgA1 (Mce) myeloma pro-
tein with well-characterized structures of O-glycans [24,29,47,66–
68,72] were added to serum from a healthy control or from an IgAN
patient, or cord-blood serum. After 1-h incubation at 4 ◦C to allow
formation of immune complexes, the mixtures were diluted with
culture medium and added to serum-starved human mesangial cells.
Cellular proliferationwasmeasuredafter 20-h incubation. The sample
with the most stimulatory activity was generated using cord-blood
serum#1 (CBS1; 2%ﬁnal concentration) supplementedwith 20μg/ml
IgA1 (Fig. 1). In control experiments, immune complexes formedwith
serum from an IgAN patient stimulated cultured human mesangial
cells to proliferate more than did the complexes formed with serum
from a healthy control (Fig. 1). Supplementation with IgA1 increased
formation of stimulatory complexes at lower serum concentrations
and, conversely, led to inhibition of proliferation when more serum
and IgA1 were used (Fig. 1). Uncomplexed IgA1 did not signiﬁcantly
affect cellular proliferation (Fig. 1), conﬁrming our previous report
[26].
Next, we optimized conditions for the formation of immune com-
plexes using cord-blood serum, based on variation of the factors
known to affect antibody–antigen reactions, such as time, temper-
ature, and antigen/antibody ratio. Thus, we varied incubation times
(1h at room temperature vs. overnight at 4 ◦C) and concentrations of
Gal-deﬁcient IgA1 (ranging from 1 to 50μg/ml). We found that the
immune complexeswithmost stimulatory activity were formed after
overnight incubation at 4 ◦C using cord-blood serum supplemented
with 10μg/ml IgA1 and we used these conditions in further experi-
ments.
In control experiments, cord-blood serum samples not supple-
mented with IgA1 showed low activity in the proliferation assay. Five
different cord-blood serum samples were used; three (CBS1, CBS3,
and CBS4) showed formation of stimulatory IgA immune complexes
after supplementation with 10μg/ml IgA1 and overnight incubation.
Formation of stimulatory IgA1 immune complexes was veriﬁed with
other cord-blood sera and the stimulatory effect was dependent on
the presence of IgG antibodies binding to Gal-deﬁcient IgA1.
To conﬁrm and extend the experiments with cord-blood serum,
we used two different Gal-deﬁcient IgA1 myeloma proteins (Mce
and Gou at 3 and 10μg/ml ﬁnal concentrations) and added an IgA1
myeloma protein to cord-blood serum (CBS3) or serum from an IgAN
patient or a healthy control (2% serum ﬁnal concentration in the cul-
ture medium) to form stimulatory immune complexes. Formation
of immune complexes was required to stimulate mesangial cells to
proliferate; only cord-blood serum or serum from an IgAN patient
Fig. 1. Proliferation of primary human mesangial cells stimulated with serum or
cord-blood serum supplemented with Gal-deﬁcient IgA1 myeloma protein . Gal-
deﬁcient IgA1 (Mce) myeloma protein was added to serum samples (ﬁnal concentra-
tions were 0.5%, 2%, and 5% serum; negative control was serum-free, denoted by 0%).
Serum sampleswere froma healthy control (Control), an IgANpatient (IgAN1), and two
samples of cord-blood serum (CBS1 and CBS2). IgA ﬁnal concentrations were 0, 20, and
50μg/ml of culture medium (marked by white, black, and gray columns, respectively).
After 1-h incubation at 4 ◦C to allow formation of immune complexes, the samples
were added with culture medium to serum-starved human mesangial cells, and cel-
lular proliferation was measured after 20-h incubation. Data for cellular proliferation
were expressed relative to the proliferation of cells with medium alone, considered 1.
Mean and SD are shown (n = 8).
supported formation of stimulatory immune complexes (Fig. 2a and
b).
IgA1 (Gou) myeloma protein has some Gal-deﬁcient O-glycans,
as does IgA1 (Mce) myeloma protein. Therefore, cord-blood serum
supplemented with either Gal-deﬁcient IgA1 protein formed com-
plexes that stimulated proliferation of mesangial cells (Fig. 2b). In
contrast, IgA2 (Fel) myeloma protein without O-glycans did not form
any complexes with cord-blood serum and did not inﬂuence prolif-
eration of mesangial cells. Based on these results, we concluded that
Gal-deﬁciency of the IgA1 O-glycans was critical for the formation of
pathogenic IgA1–IgG complexes.
3.2. In vitro-formed immune complexes resemble those in sera of
patients with IgAN
To further characterize the formed IgA1–IgG complexes, we used
80μg Gal-deﬁcient IgA1 (Mce) myeloma protein (ﬁnal concentration
10μg/ml in the culturemedium) and 160μl cord-blood serum (CBS3)
and incubated themixture overnight at 4 ◦C to allow formation of im-
mune complexes. Cord-blood serum without added IgA1 served as a
negative control. To determine the size of immune complexes that in-
duced proliferation of mesangial cells, the samples were fractionated
on a calibrated Superose 6 column and the resultant fractions were
added to serum-starvedmesangial cells.Wedetermined that immune
complexes >700kDa were stimulatory and distributed in two peaks
(fractions 32–36 and fractions 38–46) (Fig. 3a). The content of IgA1
and IgG–IgA1 immune complexes in these fractions was determined
by ELISA (Fig. 3b and c). The stimulatory fractions contained IgA1–IgG
immune complexes.
For comparison, we also analyzed, in parallel, immune complexes
isolated from serum samples of three patients with IgAN. Native
serum samples were fractionated on the same Superose 6 column;
resultant fractions were added to serum-starved mesangial cells and
cellular proliferation was measured after 20-h incubation. As shown
in Fig. 4, sera of each patient contained stimulatory IgA-containing
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Fig. 2. Proliferation of humanmesangial cells stimulatedwith immune complexes
formed in vitro using serum samples supplemented with different IgA1 myeloma
proteins. Two different Gal-deﬁcient IgA1 myeloma proteins, Mce and Gou (3 and
10μg/ml ﬁnal concentration), were added to cord-blood serum (CBS3), or serum from
an IgAN patient or a healthy control (2% serum ﬁnal concentration in the culture
medium). After overnight incubation at 4 ◦C to allow formation of immune complexes,
the samples were added to serum-starved human mesangial cells, and cellular prolif-
eration was measured after 20-h incubation. Controls included stimulation with IgA1
proteins alone. Panel (a) shows proliferation with IgA1 proteins without allowing time
for immune complex formation in serum samples (no complexes were formed) and
panel (b) shows proliferation with IgA1-containing immune complexes. The changes
in proliferation are shown as difference in thymidine uptake between a sample and a
mock control (mock-treatment with no IgA1 added) (Δcpm). Mean and SD are shown
(n = 6).
immunecomplexes, predominantly in the large-molecular-mass frac-
tions >700kDa (fractions 22–36). In a control experiment, we re-
moved IgA1 from the serum sample by jacalin-afﬁnity chromatogra-
phy before fractionation; most of the stimulatory activity was lost.
Together, these experiments showed that cord-blood serum con-
tained IgG speciﬁc for Gal-deﬁcient IgA1 and that addition of Gal-
deﬁcient IgA1 to cord-blood serum led to formation of biologically ac-
tive immune complexes of large molecular mass. Functionally, these
formed complexes were similar to the IgA1-containing complexes in
the circulation of IgAN patients.
3.3. Formation of stimulatory IgA1-containing immune complexes
requires a heat-sensitive serum factor
To extend our understanding of properties of IgA1-containing im-
mune complexes, we formed IgA1 immune complexes using native
or heat-inactivated cord-blood serum (CBS4). The samples were then
fractionated by size-exclusion chromatography as before and their
biological activities were measured using the proliferation assay.
As shown in Fig. 5, the ability of cord-blood serum to form IgA1-
containing stimulatory immunecomplexesdecreased signiﬁcantly af-
ter heat inactivation (Fig. 5a). Interestingly, immune complexes were
formedwith both the native andheat-inactivated serum samples (Fig.
Fig. 3. Proliferation of humanmesangial cells stimulatedwith immune complexes
formed in vitro using cord-blood serum supplemented with Gal-deﬁcient IgA1
myeloma protein. Gal-deﬁcient IgA1 (Mce) myeloma protein (80μg, ﬁlled circles,
corresponding to ﬁnal concentration of 10μg/ml culturemedium)was added to 160μl
cord-blood serum. After overnight incubation at 4 ◦C to allow formation of immune
complexes, the samples were fractionated on a calibrated Superose 6 column, and the
resultant fractionswere ﬁlter-sterilized and added to serum-starved humanmesangial
cells. Cellular proliferation was measured after overnight incubation. Panel (a) shows
relative cellular proliferation (empty circles represent activity of cord-blood serum
without any supplementation), panel (b) shows IgA concentration, and panel (c) shows
the amount of IgG–IgA immune complexes in the collected fractions. V0, void volume.
5b and c), but the complexes formed in heat-inactivated serum were
of larger molecular mass (Fig. 5c).
In summary, these studies showed that Gal-deﬁcient IgA1, anti-
IgA1 antibodies of IgG isotype, and a heat-sensitive serum factor are
necessary for in-vitro formation of biologically active immune com-
plexes.
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Fig. 4. Proliferation of human mesangial cells stimulated with fractions of serum
from three patientswith IgAN. Native-serum samples from three IgAN patients (ﬁlled
circles in panels a, b, and c) were fractionated on a calibrated Superose 6 column; the
fractions were ﬁlter-sterilized and added to serum-starved human mesangial cells.
Cellular proliferation wasmeasured after 20-h incubation. IgA-depleted serum sample
from one IgAN patient (empty circles in panel a) served as a negative control.
4. Discussion
In this study, we demonstrated that biologically active immune
complexes, functionally analogous to those present in sera of pa-
tientswith IgAN, can be formed in vitro using components not derived
from IgAN patients: Gal-deﬁcient IgA1 myeloma proteins with pre-
cisely deﬁned glycan structures [29,47,66–68,72] and cord-blood IgG
from healthy women as a source of anti-glycan antibodies. Therefore,
these results conﬁrm and provide further structural and functional
support for the role of immune complexes in sera of IgAN patients
in the pathogenesis of their renal disease. As the amounts of im-
mune complexes that can be obtained from sera of IgAN patients are
modest, this protocol will facilitate quantitative analytical and struc-
tural studies of pathogenic IgA1-containing complexes. Generation
of large amounts of such complexes in vitro will allow investigators
Fig. 5. Proliferation of human mesangial cells stimulated with fractions of na-
tive or heat-inactivated cord-blood serum supplemented with Gal-deﬁcient IgA1
myeloma protein. Gal-deﬁcient IgA1 (Mce) myeloma protein (80μg) was added to
160μl of native (ﬁlled circles) or heat-inactivated (empty circles) cord-blood serum.
After overnight incubation at 4 ◦C to allow formation of immune complexes, the sam-
ples were fractionated on a calibrated Superose 6 column, and the resultant fractions
were ﬁlter-sterilized and added to serum-starved human mesangial cells, and cellu-
lar proliferation was measured. Panel (a) shows relative cellular proliferation. Panel
(b) shows IgA concentration and panel (c) the amount of IgG–IgA complexes in the
collected fractions. V0, void volume. Results of one of the two experiments are shown.
to deﬁne in detail the precise localization of glycan-dependent epi-
topes in the Gal-deﬁcient IgA1 hinge regions as well as speciﬁcities
of the corresponding anti-glycan antibodies. The glycan structures
of IgA1 myeloma proteins used in this study have been determined
[29,44,66,67]. We propose that researchers exploit this information
in the design of hinge-region glycopeptide structures to prevent for-
mation of nephritogenic immune complexes [24].
We have shown that anti-glycan antibodies that can bind to Gal-
deﬁcient IgA1 are present in sera of healthy controls, but levels are
higher in sera from patients with IgAN [44]. We screened cord-blood
sera and found that three of the ﬁve samples also contained these
anti-glycan IgG antibodies. The origin of the glycan-speciﬁc anti-
bodies in sera of these apparently healthy mothers remains unclear.
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However, some viruses and bacteria express N-acetylgalactosamine-
containing molecules on their surface in structures comparable to
that of the hinge-region O-linked glycans of Gal-deﬁcient IgA1 (for
review see [27,44,49,65,73,74]). Accordingly, we speculate that an
infection with one of these microorganisms induced production of
glycan-speciﬁc antibodies that cross-react with Gal-deﬁcient IgA1
[27,44,49,65]. Cord-blood serum containsmaternal IgG, but other im-
munoglobulins are absent or present in only trace amounts. Further-
more, there were no intrinsic immune complexes that stimulated
cellular proliferation of the cultured mesangial cells. Therefore, we
tested the possibility of in-vitro formation of biologically active IgA1-
containing immune complexes, with the overall goal to characterize
the conditions necessary for production of stimulatory complexes
that mimic the properties of complexes in the circulation of patients
with IgAN.
We have deﬁned the conditions that resulted in the formation
of IgA1-containing immune complexes that stimulated proliferation
of the mesangial cells. Importantly, in-vitro-generated immune com-
plexes that displayed stimulatory activity for cultured humanmesan-
gial cells exhibited molecular properties of stimulatory immune
complexes present in sera of IgAN patients. When used alone, Gal-
deﬁcient IgA1 or puriﬁed cord-blood IgG did not stimulate prolifera-
tion of mesangial cells. Additional control experiments revealed that
puriﬁed cord-blood IgG and puriﬁed Gal-deﬁcient IgA1 formed im-
mune complexes in the absence of sera, but these complexeswere not
stimulatory. These experiments thus showed that cord-blood serum
was necessary for generation of stimulatory IgA1–IgG immune com-
plexes. However, when the cord-blood serum was heat-inactivated,
immune complexes still formed, but did not activate mesangial cells.
These results together showed that formation of the IgA1-containing
biologically active immune complexes required Gal-deﬁcient IgA1,
anti-IgA1 IgG antibody, and a heat-sensitive serum factor. Although
we tried to identify this heat-sensitive factor by routine proteomic
approaches, the results were inconclusive. Therefore, future experi-
ments will be needed to identify this factor(s). We speculate, based
on the heat-sensitivity characteristic, that it may be a complement-
regulating protein that affects the size of the formed complexes.
To elucidate the nature of interactions between IgA1–IgG immune
complexes and mesangial cells, one would need to know the com-
ponents of the immune complexes and the identities of receptors on
mesangial cells. Mesangial cells do not express CD89 or asialogly-
coprotein receptor but do express CD71, a transferrin receptor that
binds polymeric IgA1 [25,26,61–63,75,76]. In another study, we used
an IgA-speciﬁc protease to generate Fab and Fc fragments from poly-
meric Gal-deﬁcient IgA1 and then, using the digested IgA1, formed
immune complexes with native cord-blood serum (Yanagihara et al.,
unpublished data). Results of these experiments indicated that Fc
fragments of IgA1 were present in the stimulatory complexes, thus
supporting the role of an IgA1 receptor(s) in the cellular activation,
likely in participation with other receptors, such as those for a heat-
sensitive serum factor(s).
In summary, these ﬁndings provide new tools for studies of the
pathogenesis of IgAN and will enable analysis of composition of the
pathogenic immune complexes as well as of the signaling pathways
induced in humanmesangial cells. Such studieswill thus have signiﬁ-
cant implications for the treatment of this common immune-complex
renal disease [27,74].
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